🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

RecruitingPhase 4Ages 18 Years - anyAllThe University of Hong Kong
NCT06324461 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Planned elective intermediate to high risk non-cardiac surgery * Anticipated to remain hospitalized for at least one night after surgery * Voluntarily agrees to participate by providing written informed consent Exclusion Criteria: * History of symptomatic hypoglycemia within 1 month of recruitment * History of pancreatitis * Diabetic retinopathy * Personal or family history of medullary thyroid carcinoma (MTC) * Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment * Stroke or transient ischemic attack within 1 month of recruitment * Known severe liver disease (Child-Pugh B or C) * Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min) * Recent use of GLP-1 RA within 1 month of recruitment * Known allergy or hypersensitivity to GLP-1 RA * Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding * Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
💊

What it tests

  • Dulaglutide 0.75mg subcutaneous injection
📍

Where

3 sites
Duchess of Kent Children's Hospital at Sandy Bay
Hong Kong, China
Queen Mary Hospital
Hong Kong, China
Tung Wah Hospital
Hong Kong, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy